A polyethylenimine-linoleic acid conjugate for antisense oligonucleotide delivery

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Xie, Jing ^a,b   Teng, Lesheng ^a,b   Yang, Zhaogang ^a   Zhou, Chenguang ^b   Liu, Yang ^b   Yung, Bryant C ^b   Lee, Robert J ^a,b  

^a JILIN UNIVERSITY   (China)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; LINOLEIC ACID; POLYETHYLENEIMINE; RIBONUCLEOTIDE REDUCTASE; MESSENGER RNA;

ARTICLE; COMPLEX FORMATION; CYTOTOXICITY TEST; DOWN REGULATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; DRUG UPTAKE; ENDOCYTOSIS; HUMAN; HUMAN CELL; INTERNALIZATION; LIGHT SCATTERING; PARTICLE SIZE; TUMOR CELL; ZETA POTENTIAL; AGAR GEL ELECTROPHORESIS; CELL DEATH; CELL LINE; CHEMISTRY; CONFOCAL MICROSCOPY; DRUG EFFECTS; FLOW CYTOMETRY; GENE TRANSFER; GENETICS; INTRACELLULAR SPACE; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATIC ELECTRICITY; WESTERN BLOTTING; DRUG EFFECT;

BLOTTING, WESTERN; CELL DEATH; CELL LINE; DOWN-REGULATION; ELECTROPHORESIS, AGAR GEL; FLOW CYTOMETRY; GENE TRANSFER TECHNIQUES; HUMANS; INTRACELLULAR SPACE; LINOLEIC ACID; MICROSCOPY, CONFOCAL; OLIGONUCLEOTIDES, ANTISENSE; POLYETHYLENEIMINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STATIC ELECTRICITY;

EID: 84879387385     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/710502     Document Type: Article

References (35)

1. Braasch D. A., Corey D. R., Novel antisense and peptide nucleic acid strategies for controlling gene expression. Biochemistry 2002 41 14 4503 4510 2-s2.0-0037046160 10.1021/bi0122112 (Pubitemid 34275650)
2. Flaherty K. T., Stevenson J. P., O'Dwyer P. J., Antisense therapeutics: lessons from early clinical trials. Current Opinion in Oncology 2001 13 6 499 505 2-s2.0-0034757838 10.1097/00001622-200111000-00013 (Pubitemid 33027903)
3. Opalinska J. B., Gewirtz A. M., Nucleic-acid therapeutics: basic principles and recent applications. Nature Reviews Drug Discovery 2002 1 7 503 514 2-s2.0-0036636074 (Pubitemid 37361504)
4. Aboul-Fadl T., Antisense oligonucleotides: the state of the art. Current Medicinal Chemistry 2005 12 19 2193 2214 2-s2.0-23844543479 10.2174/ 0929867054864859 (Pubitemid 41179707)
5. Davidson B. L., McCray P. B., Current prospects for RNA interference-based therapies. Nature Reviews Genetics 2011 12 5 329 340 2-s2.0-79954580272 10.1038/nrg2968
6. Stein C. A., Cheng Y. C., Antisense oligonucleotides as therapeutic agents-is the bullet really magical? Science 1993 261 5124 1004 1012 2-s2.0-0027376439 (Pubitemid 23300859)
7. Mani S., Rudin C. M., Kunkel K., Holmlund J. T., Geary R. S., Kindler H. L., Dorr F. A., Ratain M. J., Phase I clinical and pharmacokinetic study of protein kinase C- α antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clinical Cancer Research 2002 8 4 1042 1048 2-s2.0-0036554842 (Pubitemid 35177353)
8. Monteleone G., Fantini M. C., Onali S., Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Molecular Therapy 2012 20 4 870 876 10.1038/mt.2011.290
9. Zent C. S., Smith B. J., Ballas Z. K., Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leukemia & Lymphoma 2012 53 2 211 217
10. Fattal E., Barratt G., Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA. British Journal of Pharmacology 2009 157 2 179 194 2-s2.0-68549104191 10.1111/j.1476-5381.2009.00148.x
11. de Rosa G., La Rotonda M. I., Nano and microtechnologies for the delivery of oligonucleotides with gene silencing properties. Molecules 2009 14 8 2801 2823 2-s2.0-69549097534 10.3390/molecules14082801
12. Agrawal S., Temsamani J., Galbraith W., Tang J., Pharmacokinetics of antisense oligonucleotides. Clinical Pharmacokinetics 1995 28 1 7 16 2-s2.0-0028850751
13. Lee Y., Vassilakos A., Feng N., Jin H., Wang M., Xiong K., Wright J., Young A., GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors. International Journal of Oncology 2006 28 2 469 478 2-s2.0-33745599493
14. Ko Y., North S., Berry S. R., Dose escalation phase of a phase I/II study of GTI-2501, an antisense to the R1 subunit of ribonucleotide reductase (RNR) and docetaxel in patients with metastatic hormone-refractory prostate cancer. Journal of Clinical Oncology 2006 24 18 98S
15. Akinc A., Thomas M., Klibanov A. M., Langer R., Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. Journal of Gene Medicine 2005 7 5 657 663 2-s2.0-19744372388 10.1002/jgm.696 (Pubitemid 40744532)
16. Boussif O., Zanta M. A., Behr J. P., Optimized galenics improve in vitro gene transfer with cationic molecules up to 1000-fold. Gene Therapy 1996 3 12 1074 1080 2-s2.0-0030462391 (Pubitemid 27036110)
17. Kircheis R., Wightman L., Schreiber A., Robitza B., Rössler V., Kursa M., Wagner E., Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application. Gene Therapy 2001 8 1 28 40 2-s2.0-0035131596 10.1038/sj.gt.3301351 (Pubitemid 32162413)
18. Boussif O., Lezoualc'h F., Zanta M. A., Mergny M. D., Scherman D., Demeneix B., Behr J. P., A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proceedings of the National Academy of Sciences of the United States of America 1995 92 16 7297 7301 2-s2.0-0029160083 10.1073/pnas.92.16.7297
19. Deng R., Yue Y., Jin F., Chen Y., Kung H. F., Lin M. C. M., Wu C., Revisit the complexation of PEI and DNA-how to make low cytotoxic and highly efficient PEI gene transfection non-viral vectors with a controllable chain length and structure? Journal of Controlled Release 2009 140 1 40 46 2-s2.0-70349820287 10.1016/j.jconrel.2009.07.009
20. Tian H., Xiong W., Wei J., Wang Y., Chen X., Jing X., Zhu Q., Gene transfection of hyperbranched PEI grafted by hydrophobic amino acid segment PBLG. Biomaterials 2007 28 18 2899 2907 2-s2.0-33947575124 10.1016/j. biomaterials.2007.02.027 (Pubitemid 46482665)
21. Boeckle S., von Gersdorff K., van der Piepen S., Culmsee C., Wagner E., Ogris M., Purification of polyethylenimine polyplexes highlights the role of free polycations in gene transfer. Journal of Gene Medicine 2004 6 10 1102 1111 2-s2.0-11844290850 10.1002/jgm.598 (Pubitemid 40228122)
22. Thomas M., Ge Q., Lu J. J., Chen J., Klibanov A. M., Cross-linked small polyethylenimines: while still nontoxic, deliver DNA efficiently to mammalian cells in vitro and in vivo. Pharmaceutical Research 2005 22 3 373 380 2-s2.0-17644401347 10.1007/s11095-004-1874-y
23. Forrest M. L., Koerber J. T., Pack D. W., A degradable polyethylenimine derivative with low toxicity for highly efficient gene delivery. Bioconjugate Chemistry 2003 14 5 934 940 2-s2.0-0141569730 10.1021/bc034014g (Pubitemid 37152952)
24. Tang G. P., Yang Z., Zhou J., Poly(ethylenimine)-grafted-poly[(aspartic acid)-co-lysine], a potential non-viral vector for DNA delivery. Journal of Biomaterials Science, Polymer Edition 2006 17 4 461 480 2-s2.0-33746412519 10.1163/156856206776374133 (Pubitemid 47279193)
25. Gharwan H., Wightman L., Kircheis R., Wagner E., Zatloukal K., Nonviral gene transfer into fetal mouse livers (a comparison between the cationic polymer PEI and naked DNA). Gene Therapy 2003 10 9 810 817 2-s2.0-0038442898 10.1038/sj.gt.3301954 (Pubitemid 36621826)
26. Kim S., Choi J. S., Jang H. S., Suh H., Park J., Hydrophobic modification of polyethyleneimine for gene transfectants. Bulletin of the Korean Chemical Society 2001 22 10 1069 1075 2-s2.0-0035540443 (Pubitemid 33358488)
27. Teng L. S., Xie J., Teng L. R., Lee R. J., Enhanced siRNA delivery using oleic acid derivative of polyethylenimine. Anticancer Research 2012 32 4 1267 1271
28. Yang Z., Sun W., Hu K., Adenosine A1 receptors selectively target protein kinase C isoforms to the caveolin-rich plasma membrane in cardiac myocytes. Biochimica et Biophysica Acta 2009 1793 12 1868 1875 2-s2.0-71749119732 10.1016/j.bbamcr.2009.10.007
29. Yang Z., Sun W., Hu K., Molecular mechanism underlying adenosine receptor-mediated mitochondrial targeting of protein kinase C. Biochimica et Biophysica Acta 2012 1823 4 950 958 10.1016/j.bbamcr.2011.12.012
30. Kim T. I., Baek J. U., Yoon J. K., Choi J. S., Kim K., Park J. S., Synthesis and characterization of a novel arginine-grafted dendritic block copolymer for gene delivery and study of its cellular uptake pathway leading to transfection. Bioconjugate Chemistry 2007 18 2 309 317 2-s2.0-33947636081 10.1021/bc0601525 (Pubitemid 46493500)
31. van der Aa M. A. E. M., Huth U. S., Häfele S. Y., Schubert R., Oosting R. S., Mastrobattista E., Hennink W. E., Peschka-Süss R., Koning G. A., Crommelin D. J. A., Cellular uptake of cationic polymer-DNA complexes via caveolae plays a pivotal role in gene transfection in COS-7 cells. Pharmaceutical Research 2007 24 8 1590 1598 2-s2.0-34250867419 10.1007/s11095-007-9287-3 (Pubitemid 46988225)
32. Zhang C., Newsome J. T., Mewani R., Pei J., Gokhale P. C., Kasid U. N., Systemic delivery and pre-clinical evaluation of nanoparticles containing antisense oligonucleotides and siRNAs. Methods in Molecular Biology 2009 480 65 83 2-s2.0-58149342080 10.1007/978-1-59745-429-2-5
33. Yu B., Zhao X., Lee J. L., Lee R. J., Targeted delivery systems for oligonucleotide therapeutics. AAPS Journal 2009 11 1 195 203 2-s2.0-65549111789 10.1208/s12248-009-9096-1
34. Li W., Szoka F. C. Jr., Lipid-based nanoparticles for nucleic acid delivery. Pharmaceutical Research 2007 24 3 438 449 2-s2.0-33847099637 10.1007/s11095-006-9180-5 (Pubitemid 46295166)
35. Karmali P. P., Chaudhuri A., Cationic liposomes as non-viral carriers of gene medicines: resolved issues, open questions, and future promises. Medicinal Research Reviews 2007 27 5 696 722 2-s2.0-34250189716 10.1002/med.20090 (Pubitemid 47282449)